The Lilly Diaspora and the Global Reach of Indiana Biosciences: Celebrating the 150th Anniversary of Eli Lilly and Company
Authored by Christopher C. Conway, Chief Philanthropy Officer & Executive Vice President of Strategic Communications
Today, the Indiana Biosciences Research Institute (IBRI) may be the clearest example anywhere of how a corporate scientific culture can evolve into an engine for innovation, collaboration, and breakthroughs.
It’s a living legacy, staked on the words and philosophy of Eli Lilly, and the foundational ethos that has brought a critical concentration of industry talent, philanthropic resources, university research, and healthcare assets to Indiana that would require trillions, yes trillions, of dollars to replicate elsewhere.
Here in Indiana, and at the IBRI, the influence of Lilly scientists and Lilly corporate values has profoundly influenced an entire life sciences economy, transformed civic leadership, and helped establish one of the world’s most unique translational research organizations.
Generations of leaders shaped by the Lilly tradition of scientific rigor, long-term thinking, operational excellence, and civic responsibility have both stayed in and strayed from Indiana.
For that reason, IBRI is a vital mover in the life sciences, while a “Lilly diaspora” is deeply embedded at peer institutions and corporations engaged in the work all over the world. They have collectively exported a culture.
Each scientist and administrator who is part of the Lilly diaspora carries with them the understanding that scientific innovation requires patience, interdisciplinary collaboration, institutional trust, and long-term investment in people and infrastructure. IBRI’s key leaders today include President and CEO Alan Palkowitz, who spent nearly three decades at Lilly, ultimately serving as Vice President of Discovery Chemistry Research and Technologies, and Senior Vice President Christina Bodurow, who began her career within Lilly Research Laboratories before moving into major global leadership roles in translational drug development and regulatory affairs. IBRI’s Vice President Louis Stancato spent more than 25 years at Lilly, including his work as an internationally recognized leader in pediatric oncology and translational drug discovery.
Additional senior leaders at IBRI further reflect the enduring influence of the Lilly tradition. Chief Financial Officer Michele Sawyer and board member Aaron Schacht both dedicated much of their careers to Lilly and Elanco, a Lilly spin-off that continues to extend Indiana’s global life sciences influence.
At the board level, John Lechleiter and Michael Harrington exemplify the lasting influence of Lilly leadership. John’s 2012 call for Indiana to create a world-class biosciences institute directly helped inspire IBRI itself, while Michael embodies the Lilly legacy of connecting scientific ambition with institutional stewardship.
Importantly, the Lilly influence at IBRI extends far beyond the boardroom and executive suite. Across both scientific and administrative staff are numerous professionals whose careers were shaped at Lilly before bringing their expertise to IBRI. The result is a shared culture rooted in scientific excellence, translational urgency, collaboration, and long-term thinking.
And at every level, IBRI benefits from the relationships gained and grown with colleagues and collaborators around the globe. Lilly alumni bring with them big aspirations and global ambitions. That is one reason IBRI is actively working with partners in Ireland, France, and Australia, with more international collaborations to come.
